Pixyl.Neuro reportedly leverages generative artificial intelligence (AI) technology to accelerate brain MRI assessment and improve early detection of abnormal atrophy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Pixyl.Neuro™, an adjunctive artificial intelligence (AI)-powered software that may enhance magnetic resonance imaging (MRI) detection and follow-up of patients with neurological disorders including Alzheimer’s disease and multiple sclerosis (MS).
Reportedly providing automated brain MRI analysis in less than five minutes, Pixyl.Neuro may help quantify brain region volume to aid in the differential diagnosis and facilitate earlier identification of atrophy, according to Pixyl, the developer of the software.
Lotfi Hacein-Bey, M.D, said adjunctive AI support reinforces radiology workflows for the assessment of patients with neurological disorders.
“The recent FDA approval of Pixyl's software is a very positive step toward improved diagnosis, management and longitudinal follow up of neurodegenerative and neuroinflammatory disorders, especially with the advent of disease-modifying treatments for MS, NMO (neuromyelitis optica) and Alzheimer's disease,” noted Dr. Hacein-Bey, the director of the Division of Neuroradiology the the University of California, Davis (UC Davis) School of Medicine in Sacramento, Calif.
Pixyl added that the Pixyl.Neuro software, currently utilized in more than 12 countries, has seen a four-fold increase in use since December 2022.
New Literature Review Finds ChatGPT Effective in Radiology in 84 Percent of Studies
April 29th 2024While noting a variety of pitfalls with the chatbot ranging from hallucinations to improper citations, the review authors found the use of ChatGPT in radiology demonstrated “high performance” in 37 out of 44 studies.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.